Voiant Expands with Acquisition of Voxeleron
Voiant, a provider of clinical trial imaging solutions based in Waltham, MA, has recently acquired Voxeleron, a company specializing in AI-driven ophthalmic image analysis and based in Austin, TX.
The financial details of the acquisition have not been disclosed.
This acquisition will enable Voiant to expedite the development of innovative treatments for eye diseases, leveraging Voxeleron’s expertise in AI-driven ophthalmic image analysis.
Voxeleron offers advanced solutions for image analysis in various fields, including medicine and biology. Their platform provides software for analyzing ophthalmic imagery, helping researchers accelerate clinical research, obtain actionable results, and improve patient outcomes.
Voiant, led by CEO Jim Primerano, is known for its AI-based clinical trial imaging solutions, providing biopharmaceutical companies with fast and high-quality clinical endpoint data delivery.
By combining their capabilities, Voiant and Voxeleron will continue to invest in advancing biomarker development and enhancing image analysis capabilities for the benefit of patients and researchers alike.
FinSMEs
18/04/2025
